Page 1870 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

70. Tseng C-Y, Wang S-L, Lai M-D, et al. Formation of morphine marker in decompensated liver cirrhosis. Clin Chem. 2002;
from codeine in Chinese subjects of different CYP2D6 geno- 48:850-858.
types. Clin Pharmacol Ther. 1996;60:177. 89. Schentag JJ, Cerra FB, Calleri GM, et al. Age, disease, and
71. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the cimetidine disposition in healthy subjects and chronically ill
debrisoquin oxidative poor metabolism phenotype in American patients. Clin Pharmacol Ther. 1981;29:737.
black versus white subjects. Clin Pharmacol Ther. 1991;50:308. 90. Bass NM, Williams RL. Guide to drug dosage in hepatic disease.
72. Flockhart DA. Drug interactions and the cytochrome p450 Clin Pharmacokinet. 1988;15:396.
system: the role of cytochrome p450 2C19. Clin Pharmacokinet. 91. Rudy AC, Brater DC. Drug interactions. In: Chernow B, ed.
1995;29:45. The Pharmacologic Approach to the Critically Ill Patient. 3rd ed.
73. Lerena AL, Alm C, Dahl ML, et al. Haloperidol disposition is Baltimore, MD: Williams & Wilkins; 1994:15.
dependent on debrisoquine hydroxylation phenotype. Ther 92. Wright JM. Drug interactions. In: Melmon KL, Morrelli HF,
Drug Monit. 1992;14:92. Hoffman BB, Nierenberg DW, eds. Melmon and Morrelli’s
74. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 Clinical Pharmacology: Basic Principles in Therapeutics. 3rd ed.
genotype and risk of adverse clinical outcomes among patients New York: McGraw-Hill; 1992:21.
treated with clopidogrel predominantly for PCI: a meta- 93. Kolars JC, Awni WM, Merion RM, Watkins PB. First-
analysis. JAMA. 2010;304:1821. pass metabolism of cyclosporine by the gut. Lancet. 1991;
75. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 338:1488.
polymorphisms and response to clopidogrel. N Engl J Med. 94. MacKichan JJ. Protein binding drug displacement interactions:
2009;360:354-362. fact or fiction? Clin Pharmacokinet. 1989;16:65.
76. Daly AK. Significance of Minor Cyt P450 3a Isoforms. Clin 95. Kaplan B, Friedman G, Jacobs M, et al. Potential interac-
Pharmacokinetic. 2006;45:13-31. tions of troglitazone and cyclosporine. Transplantation. 1998;
77. Evans WE, McLeod HL. Drug therapy: pharmacogenomics— 65:1399.
drug disposition, drug targets, and side effects. N Engl J Med. 96. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios
2003;348:538. A, Giannoglou GD. Risk factors and drug interactions predis-
78. Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine posing to statin-induced myopathy. Drug Safety. 2010;33(3):
metabolism, toxic effects, and dosage requirement in a thiopu- 171-187.
rine methyltransferase-deficient child with acute lymphocytic 97. Thompson D, Oster G. Use of terfenadine and contraindicated
leukemia. J Pediatr. 1991;119:985. drugs. JAMA. 1996;275:1339.
79. Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive 98. Pearson TF, Pittman DG, Longley JM, et al. Factors associated
analysis of thiopurine S-methyltransferase phenotype-geno- with preventable adverse drug reactions. Am J Hosp Pharm.
type correlation in a large population of German-Caucasians 1994;51:2268.
and identification of novel TPMT variants. Pharmacogenetics. 99. Wood AJJ. Adverse reactions to drugs. In: Isselbacher KJ,
2004;14:407. Braunwald E, Wilson JD, et al. eds. Harrison’s Principles of
80. Keogh A, Spratt P, McCosker C, et al. Ketoconazole reduces the Internal Medicine. 13th ed. New York: McGraw-Hill; 1994:25.
need for cyclosporine after cardiac transplantation. N Engl J 100. Cox ZL. Adverse drug events during AKI and its recovery. Clin
Med. 1995;333:628. J Am Soc Nephrol. 2013;8:1070-1078.
81. Gomez DY, Wacher VJ, Tomlanovich SJ, et al. The effects of 101. Cribb AE, Lee BL, Trepanier LA, Speilberg SP. Adverse reac-
ketoconazole on the intestinal metabolism and bioavailability tions to sulphonamide and sulphonamide-trimethoprim anti-
of cyclosporine. Clin Pharmacol Ther. 1995;58:15. microbials: clinical syndromes and pathogenesis. Adverse Drug
82. Gupta E, Wang X, Ramirez J, Ratain MJ. Modulation of gluc- React Toxicol Rev. 1996;15:9.
uronidation of SN-38, the active metabolite of irinotecan, by 102. Rieder MJ. Immunopharmacology and adverse drug reactions.
valproic acid and phenobarbital. Cancer Chemother Pharmacol. J Clin Pharmacol. 1993;33:316.
1997;39:440.
103. Amstutz U Ross CJ, Castro-Pastrana LI, et al. HLA-A 31:01 and
83. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharma- HLA-B 15:02 as genetic markers for carbamazepine hypersensi-
codynamic considerations in patients with liver disease. Clin tivity in children. Clin Pharmacol Ther. 2013;94:142.
Pharmacokinet. 1995;29:370.
104. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med.
84. Murray M. P450 enzymes. Inhibition mechanisms, genetic 2005;352:1112-1120.
regulation and effects of liver disease. Clin Pharmacokinet. 105. Bonfiglio MF, Traeger SM, Kier KL, et al. Thrombocytopenia in
1992;23:132.
intensive care patients: a comprehensive analysis of risk factors
85. Verbeeck RK, Pharmacokinetics and dosage adjustment in in 314 patients. Ann Pharmacother. 1995;29:835.
patients with hepatic dysfunction. Eur J Clin Pharmacol. 106. Krishnan V, Corbridge T, Murray P. Critical care pharmacology.
2008;64(12):1147.
In: Hall JB, Schmidt GA, Wood LDH, eds. Principles of Critical
86. Huet P-M, Villeneuve J-P. Determinants of drug disposition in Care. 3rd ed. New York: McGraw-Hill; 2005:1547.
patients with cirrhosis. Hepatology. 1983;3:913. 107. Bates DW, Gawande AA. Improving safety with information
87. Wilkinson GR, Shand DG. Commentary: a physiological approach technology. N Engl J Med. 2003;348:2526.
to hepatic drug clearance. Clin Pharmacol Ther. 1975;18:377. 108. Pronovost PJ, Waters H, Dorman T. Impact of critical care phy-
88. Orlando R, Mussap M, Plebani M, et al. Diagnostic sician workforce for intensive care unit physician staffing. Curr
value of plasma cystatin C as a glomerular filtration Opin Critical Care. 2001;7:456.

Section11-O-Ref.indd 3 12/10/2014 8:08:27 PM